Market Research Report
AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022
|Published by||GlobalData||Product code||244300|
|Published||Content info||37 Pages
|AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022|
|Published: April 30, 2012||Content info: 37 Pages||
This publication has been discontinued on February 2, 2017.
GlobalData's pharmaceuticals report, "AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022" provides AAB-001 global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2022). The report also includes information on Alzheimer's disease market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
AAB-001, bapineuzumab, anti-amyloid monoclonal antibody, Johnson & Johnson, Pfizer, Alzheimer's disease